We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+12.57%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$750M
AUM Growth
+$262M
Cap. Flow
+$205M
Cap. Flow %
27.3%
Top 10 Hldgs %
28.71%
Holding
137
New
15
Increased
36
Reduced
40
Closed
5

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$14.3M
2
ALGN icon
Align Technology
ALGN
+$13.8M
3
WBA
Walgreens Boots Alliance
WBA
+$13.5M
4
AMGN icon
Amgen
AMGN
+$12M
5
CNC icon
Centene
CNC
+$9.49M

Top Sells

Rank Stock Value
1
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$4.67M
2
SYK icon
Stryker
SYK
+$4.15M
3
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$1.91M
4
BDX icon
Becton Dickinson
BDX
+$1.79M
5
ZBH icon
Zimmer Biomet
ZBH
+$1.75M

Sector Composition

Rank Sector Weight
1 Healthcare 92.09%
2 Financials 0.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
101
United Therapeutics
UTHR
$22.6B
$1.06M 0.14%
7,800
– –
MDCO
102
DELISTED
Medicines Co
MDCO
$1.05M 0.14%
+21,500
New +$981K
GKOS icon
103
Glaukos
GKOS
$9.2B
$1.03M 0.14%
20,000
– –
ICPT
104
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$961K 0.13%
8,500
– –
INO icon
105
Inovio Pharmaceuticals
INO
$88.9M
$953K 0.13%
12,000
-917
-7% -$73.1K
JUNO
106
DELISTED
Juno Therapeutics, Inc.
JUNO
$821K 0.11%
37,000
– –
NVRO
107
DELISTED
NEVRO CORP.
NVRO
$815K 0.11%
8,700
– –
EVHC
108
DELISTED
Envision Healthcare Holdings Inc
EVHC
$799K 0.11%
13,026
– –
QTNT
109
DELISTED
Quotient Limited Ordinary Shares
QTNT
$769K 0.1%
2,750
– –
MOH icon
110
Molina Healthcare
MOH
$11.9B
$752K 0.1%
16,500
– –
GWPH
111
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$726K 0.1%
6,000
– –
HCSG icon
112
Healthcare Services Group
HCSG
$1.73B
$711K 0.09%
16,500
-21,600
-57% -$888K
ALDR
113
DELISTED
Alder Biopharmaceuticals
ALDR
$686K 0.09%
33,000
– –
DVA icon
114
DaVita
DVA
$15.2B
$680K 0.09%
10,000
– –
PODD icon
115
Insulet
PODD
$11.5B
$646K 0.09%
15,000
– –
VAR
116
DELISTED
Varian Medical Systems, Inc.
VAR
$638K 0.09%
7,000
-983
-12% -$82K
IART icon
117
Integra LifeSciences
IART
$1.49B
$632K 0.08%
+15,000
New +$641K
CEMP
118
DELISTED
Cempra, Inc.
CEMP
$619K 0.08%
+165,000
New +$572K
CLDX icon
119
Celldex Therapeutics
CLDX
$2.78B
$578K 0.08%
10,667
– –
RMD icon
120
ResMed
RMD
$28.5B
$576K 0.08%
8,000
– –
TBPH icon
121
Theravance Biopharma
TBPH
$877M
$531K 0.07%
14,428
-1,000
-6% -$31.9K
TDOC icon
122
Teladoc Health
TDOC
$1.71B
$500K 0.07%
+20,000
New +$416K
HIND
123
Vyome Holdings
HIND
$15.2M
– –
0
– –
LFWD icon
124
ReWalk Robotics
LFWD
$21.8M
$420K 0.06%
95
– –
PEN icon
125
Penumbra
PEN
$12.5B
$417K 0.06%
5,000
– –
2 3 4
5
6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2017 Portfolio in Review

As of Q1 2017, Bellevue Group held 137 positions worth $750M, up 54% from $488M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Bellevue Group deployed $205M of net new capital in Q1 2017, opening 15 new positions and adding to 36 existing holdings. Its largest new stake was Align Technology: 136,200 shares worth $15.6M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 92% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Stryker, an estimated $4.15M trimmed.

  • Bellevue Group's largest Q1 2017 buy was Align Technology: 136,200 shares worth $15.6M.
  • Bellevue Group added most to Elevance Health in Q1 2017, an estimated $14.3M increase.
  • Bellevue Group's biggest Q1 2017 reduction was Stryker, cutting an estimated $4.15M.
  • Bellevue Group fully exited Ariad Pharmaceuticals Inc in Q1 2017, selling an estimated $4.67M.
  • Bellevue Group's ten largest holdings make up 29% of its $750M portfolio in Q1 2017.
  • Bellevue Group opened 15 new positions and closed 5 in Q1 2017.
  • Bellevue Group's portfolio value rose 54% quarter-over-quarter to $750M.

Based on Bellevue Group's 13F filing for Q1 2017, filed 11 May 2017.